Charles Zhu
Stock Analyst at Guggenheim
(2.82)
# 1,946
Out of 5,105 analysts
27
Total ratings
56.52%
Success rate
23.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $9.35 | +28.34% | 4 | Oct 24, 2025 | |
| MRUS Merus | Downgrades: Market Perform | $97 | $96.93 | +0.07% | 7 | Sep 30, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $14.09 | +56.14% | 1 | Jun 18, 2025 | |
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $2.14 | - | 1 | Dec 13, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.40 | +757.14% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $104.72 | -46.52% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.70 | +285.96% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $42.11 | -38.26% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $34.03 | -5.97% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $25.48 | -45.05% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $9.35
Upside: +28.34%
Merus
Sep 30, 2025
Downgrades: Market Perform
Price Target: $97
Current: $96.93
Upside: +0.07%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $14.09
Upside: +56.14%
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.14
Upside: -
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.40
Upside: +757.14%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $104.72
Upside: -46.52%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.70
Upside: +285.96%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $42.11
Upside: -38.26%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $34.03
Upside: -5.97%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $25.48
Upside: -45.05%